LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat

Diabetologia

Volumn 51, Issue 5, 2008, Pages 882-891

  Figarola, J L ^a   Loera, S ^a   Weng, Y ^a   Shanmugam, N ^a   Natarajan, R ^a   Rahbar, S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

AGE inhibition; Diabetic nephropathy; Dyslipidaemia; Extracellular matrix; Glomerulosclerosis; Glycation; Oxidative stress; Renal fibrosis; Renal protection; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LR 90; MITOGEN ACTIVATED PROTEIN KINASE; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DYSLIPIDEMIA; GLOMERULOSCLEROSIS; HISTOLOGY; HYPERGLYCEMIA; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY FUNCTION; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BUTYRATES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; HEART RATE; KIDNEY; KIDNEY FUNCTION TESTS; RATS; RATS, ZUCKER; TRIGLYCERIDES;

EID: 41849106402     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-008-0935-x     Document Type: Article

References (51)

1. Friedman EA, Friedman AL (2007) Is there really good news about pandemic diabetic nephropathy? Nephrol Dial Transplant 22:681-683
2. Rossing P (2006) Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 6:479-483
3. Lehmann R, Schleicher ED, Lehmann R, Schleicher ED (2000) Molecular mechanism of diabetic nephropathy. Clin Chim Acta 297:135-144
4. Raptis AE, Viberti G (2001) Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 109(Suppl 2):S424-S437
5. Thomas MC, Forbes JM, Cooper ME (2005) Advanced glycation end products and diabetic nephropathy. Am J Ther 12:562-572
6. Bohlender JM, Franke S, Stein G, Wolf G (2005) Advanced glycation end products and the kidney. Am J Physiol 289:F645-F659
7. Horie K, Miyata T, Maeda K et al (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100:2995-3004
8. Tanji N, Markowitz GS, Fu C et al (2000) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11:1656-1666
9. Jensen LJ, Ostergaard J, Flyvbjerg A (2005) AGE-RAGE and AGE cross-link interaction: important players in the pathogenesis of diabetic kidney disease. Horm Metab Res 37(Suppl 1):26-34
10. Tan AL, Forbes JM, Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27:130-143
11. Peterson RG Shaw WN, Neel MA et al (1990) Zucker diabetic fatty as a model for non-insulin dependent diabetes mellitus. ILAR News 32:16-19
12. Kasiske BL, O'Donnell MP, Keane WF (1992) The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19(Suppl 1):I110-I115
13. Vora JP, Zimsen SM, Houghton DC, Anderson S (1996) Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol 7:113-117
14. Coimbra TM, Janssen U, Grone HJ et al (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 571:167-182
15. Chander PN, Gealekman O, Brodsky SV et al (2004) Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 15:2391-2403
16. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH (2000) Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58:2341-2350
17. Baylis C, Atzpodien EA, Freshour G, Engels K (2003) Peroxisome proliferator-activated receptor γ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307:854-860
18. Mizuno M, Sada T, Kato M, Koike H (2002) Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 25:271-278
19. Wihler C, Schäfer S, Schmid K et al (2005) Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia 48:1645-1653
20. Schäfer S, Linz W, Vollert H et al (2004) The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy. Diabetologia 47:98-103
21. Schrijvers BF, Flyvbjerg A, Tilton RG et al (2006) A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 21:324-329
22. Rahbar S, Figarola JL (2003) Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 419:63-79
23. Rahbar S (2007) Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys 48:147-157
24. Figarola JL, Scott S, Loera S et al (2003) LR-90, a novel advanced glycation endproduct inhibitor, prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46:1140-1152
25. Figarola JL, Rahbar S, Scott S et al (2005) Prevention of early renal disease, dyslipidemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes Metab Res Rev 21:533-544
26. Figarola JL, Shanmugam N, Natarajan R, Rahbar S (2007) Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 56:647-655
27. Wilkinson-Berka JL, Kelly DJ, Koerner SM et al (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) rat. Diabetes 51:3283-3289
28. Ohga S, Shikata K, Yozai K et al (2006) Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am J Physiol 292:F1141-F1150
29. Reckelhoff JF, Kanji V, Racusen LC et al (1998) Vitamin E ameliorates enhanced renal lipid peroxidation and accumulation of F2-isoprostanes in aging kidneys. Am J Physiol 274:R767-R774
30. Chuang L, Guh J (2001) Extracellular signals and intracellular pathways in diabetic nephropathy. Nephrology 6:165-172
31. Thomas MC, Atkins RC (2006) Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 66:2213-2234
32. Song JH, Cha SH, Hong SB, Kim DH (2006) Dual blockade of the rennin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens Suppl 24:S101-S106
33. Davis BJ, Forbes JM, Thomas MC et al (2004) Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47:89-97
34. Wu YG, Lin H, Qian H et al (2006) Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflamm Res 55:192-199
35. Forbes JM, Fukami K, Cooper ME (2007) Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 115:69-84
36. Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14:1358-1373
37. Reeves WB, Andreoli TE (2000) Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci U S A 97:7667-7669
38. Wahab NA, Yevdokimova N, Weston BS et al (2001) Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 359:77-87
39. Pugliese G, Pricci F, Romeo G et al (1997) Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 46:1881-1887
40. Zhou G, Li C, Cai L (2004) Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol 165:2033-2043
41. Crean JK, Finlay D, Murphy M et al (2002) The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J Biol Chem Nov 277:44187-44194
42. Fujita H, Omori S, Ishikura K et al (2004) ERK and p38 mediate high-glucose-induced hypertrophy and TGF-β expression in renal tubular cells. Am J Physiol 286:F120-F126
43. Zill H, Bek S, Hofmann T et al (2003) RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun 300:311-315
44. Yeh CH, Sturgis L, Haidacher J et al (2001) Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50:1495-1504
45. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14(Suppl 3):S241-S245
46. Suzaki Y, Ozawa Y, Kobori H (2006) Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci 3:40-46
47. Chang JM, Kuo MC, Kuo HT et al (2005) Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. J Lab Clin Med 146:210-215
48. Abrass CK (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46-53
49. Rosario RF, Prabhakar S (2006) Lipids and diabetic nephropathy. Curr Diab Rep 6:455-462
50. Lassila M, Seah KK, Allen TJ et al (2004) Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15:2125-2138
51. Dominguez JH, Tang N, Xu W et al (2000) Studies of renal injury III: lipid-induced nephropathy in type II diabetes. Kidney Int 57:92-104